Cutaquig
openFDA label record#
This page contains supplementary openFDA label data. For the canonical label presentation, use the corresponding DailyMed Structured Product Label.
Verified complete openFDA source JSON
- Brand name
- Cutaquig
- Generic name
- IMMUNOGLOBULIN G
- Manufacturer
- Pfizer Laboratories Div Pfizer Inc
- Product type
- PLASMA DERIVATIVE
- SPL set ID
- f199187a-de4e-2047-0aee-b6d93390b3d2
- SPL ID
- 65f206aa-2273-42cd-affc-abbd9f43500c
- Version
- 15
- Effective date
- 2025-03-24
- Source export date
- 2026-11-13
- Source partition
- 8
- Source file
- https://download.open.fda.gov/drug/label/drug-label-0008-of-0014.json.zip
- Source object key
- raw/openfda/drug-label/2026-11-13/5b373538593b900129b6789b4289137dca62e689b6d06cab0e8e33844e7e2588/drug-label-0008-of-0014.json.zip
- Source manifest SHA-256
- 8f2b6d063d44586cf97cedcdf1bdf9e261cc88632cc6855424b801bb206208d7
- Import run
- 20261116T150851Z
- Imported at
- 2026-11-16 16:55:24
| Harmonized routes |
|---|
| SUBCUTANEOUS |
Harmonized identifier links#
Every typed identifier imported from the complete openFDA harmonization object is paginated here; values are not reduced to a first match.
| Type | Scope | Identifier | Source field |
|---|---|---|---|
| rxcui | 2167152 | openfda.rxcui | |
| rxcui | 2167164 | openfda.rxcui | |
| rxcui | 2167158 | openfda.rxcui | |
| rxcui | 2167161 | openfda.rxcui | |
| rxcui | 2167159 | openfda.rxcui | |
| rxcui | 2167165 | openfda.rxcui | |
| rxcui | 2167162 | openfda.rxcui | |
| spl id | 65f206aa-2273-42cd-affc-abbd9f43500c | id | |
| spl set id | f199187a-de4e-2047-0aee-b6d93390b3d2 | set_id | |
| unii | 66Y330CJHS | openfda.unii |
Boxed warning cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
WARNING: THROMBOSIS Thrombosis may occur with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in the absence of known risk factors. [see Warnings and Precautions ( 5.2 ), Patient Counseling Information ( 17 ) ] For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity. [see Warnings and Precautions ( 5.2 )] WARNING: THROMBOSIS See full prescribing information for complete boxed warning Thrombosis may occur with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling vascular catheters, hyperviscosity, and cardiovascular risk factors. For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk of hyperviscosity.
Warnings cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
warnings and cautions
5 WARNINGS AND PRECAUTIONS Hypersensitivity and anaphylactic reactions can occur with CUTAQUIG. IgA-deficient patients with anti-IgA antibodies are at greater risk of severe reactions. ( 5.1 ) Falsely elevated blood glucose readings may occur during and after the infusion of CUTAQUIG with some glucometer and test strip systems. ( 5.3 ) Aseptic meningitis syndrome (AMS) may occur within 2 days of treatment. ( 5.4 ) Monitor patients for signs and symptoms of renal dysfunction. Monitor blood urea nitrogen, serum creatinine, and urine output in patients at risk of acute renal failure. ( 5.5 ) Monitor for clinical signs and symptoms of hemolysis, especially in patients with pre-existing anemia and/or cardiovascular or pulmonary compromise. ( 5.6 ) Monitor for pulmonary adverse reactions (transfusion-related acute lung injury, TRALI). ( 5.7 ) CUTAQUIG is made from human plasma and may carry a risk of transmitting infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent, and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. ( 5.8 ) 5.1 Hypersensitivity Severe hypersensitivity reactions may occur with CUTAQUIG, even in patients who tolerated previous treatment with human immune globulin. If a hypersensitivity reaction occurs, discontinue the CUTAQUIG infusion immediately and initiate appropriate treatment. Have epinephrine immediately available to treat any severe acute hypersensitivity reaction. IgA-deficient patients with known anti-IgA antibodies have a higher risk of developing potentially severe hypersensitivity and/or anaphylactic reactions (including anaphylaxis and shock) with administration of CUTAQUIG. CUTAQUIG contains on average 0.206 mg of IgA /mL. 5.2 Thrombosis Thrombosis may occur following treatment with immune globulin products, including CUTAQUIG. Risk factors may include: advanced age, prolonged immobilization, hypercoagulable conditions, history of venous or arterial thrombosis, use of estrogens, indwelling central vascular catheters, hyperviscosity, and cardiovascular risk factors. Thrombosis may occur in absence of known risk factors. Consider baseline assessment of blood viscosity in patients at risk for hyperviscosity, such as those with cryoglobulins, fasting chylomicronemia/markedly high triglycerides, or monoclonal gammopathies. For patients at risk of thrombosis, administer CUTAQUIG at the minimum dose and infusion rate practicable. Ensure adequate hydration in patients before administration. Monitor for signs and symptoms of thrombosis and assess blood viscosity in patients at risk for hyperviscosity. [see WARNING , Patient Counseling Information ( 17 )] 5.3 Falsely Elevated Glucose Readings Blood Glucose Testing: Some types of blood glucose testing systems (for example, those based on the glucose dehydrogenase pyrroloquinolinequinone (GDH-PQQ) or glucose-dye-oxidoreductase methods) falsely interpret the maltose contained in CUTAQUIG as glucose. This may potentially result in falsely elevated glucose readings and, consequently, in the inappropriate administration of insulin, resulting in life-threatening hypoglycemia. Also, cases of true hypoglycemia may go untreated if the hypoglycemic state is masked by falsely elevated glucose readings. Accordingly, when administering CUTAQUIG, measure blood glucose with a glucose-specific method. The product information of the blood glucose testing system, including that of the test strips, should be carefully reviewed to determine if the system is appropriate for use with maltose-containing parenteral products. If any uncertainty exists, contact the manufacturer of the testing system to determine if the system is appropriate for use with maltose-containing parenteral products. 5.4 Aseptic Meningitis Syndrome (AMS) Aseptic Meningitis Syndrome can occur with CUTAQUIG. AMS has been reported after the use of human immune globulin administered intravenously and subcutaneously. It usually begins a few hours to 2 days following treatment and occurs more frequently in females than in males. AMS is characterized by the following signs and symptoms: severe headache, nuchal rigidity, drowsiness, fever, photophobia, painful eye movements, nausea and vomiting. Cerebrospinal fluid (CSF) studies frequently show pleocytosis up to several thousand cells per mm 3 , predominantly from the granulocytic series, and elevated protein levels up to several hundred milligram/dL, but negative culture results. To rule out other causes of meningitis, conduct a thorough neurological examination on patients showing such symptoms and signs, including CSF studies. Discontinuation of immunoglobulin treatment has resulted in remission of AMS within several days without sequelae. 5.5 Renal Dysfunction/Failure Acute renal dysfunction/failure, acute tubular necrosis, proximal tubular nephropathy, osmotic nephrosis and death may occur with use of human immune globulin, especially those containing sucrose. CUTAQUIG does not contain sucrose. Ensure that patients are not volume-depleted before administration of CUTAQUIG. In patients at risk of developing renal dysfunction because of any degree of preexisting renal insufficiency or predisposition to acute renal failure (such as diabetes mellitus, age greater than 65 years, volume depletion, sepsis, paraproteinemia, or patients receiving known nephrotoxic drugs) monitor renal function and consider lower, more frequent dosing [see Dosage and Administration ( 2 ), Patient Counseling Information ( 17 )]. Periodic monitoring of renal function and urine output is particularly important in patients judged to have a potential increased risk of developing acute renal failure. Assess renal function, including measurements of blood urea nitrogen (BUN) and serum creatinine, before the initial infusion of CUTAQUIG and again at appropriate intervals thereafter. If renal function deteriorates, consider discontinuing CUTAQUIG. 5.6 Hemolysis IgG products, including CUTAQUIG, can contain blood group antibodies that may act as hemolysins and induce in vivo coating of red blood cells (RBCs) with immunoglobulin, causing a positive direct antiglobulin (Coombs’) test result. Delayed hemolytic anemia can develop subsequent to immune globulin therapy due to enhanced RBC sequestration, and acute hemolysis, consistent with intravascular hemolysis, has been reported. Monitor CUTAQUIG recipients for clinical signs and symptoms of hemolysis, particularly patients with risk factors (such as non-O blood group, administration of high IgG doses (≥ 2g/kg BW)). Underlying inflammatory state in a patient may increase the risk of hemolysis but its role is uncertain. Consider appropriate confirmatory laboratory testing if signs and symptoms of hemolysis are present after CUTAQUIG infusion. 5.7 Transfusion-related Acute Lung Injury (TRALI) Non-cardiogenic pulmonary edema may occur in patients administered human immune globulin products. TRALI is characterized by severe respiratory distress, pulmonary edema, hypoxemia, normal left ventricular function, and fever. Typically, it occurs within 1 to 6 hours following transfusion. Monitor patients for pulmonary adverse reactions. If TRALI is suspected, perform appropriate tests for the presence of anti-neutrophil antibodies in both the product and patient’s serum. Patients with TRALI may be managed using oxygen therapy with adequate ventilatory support. 5.8 Transmittable Infectious Agents Because CUTAQUIG is made from human plasma, it may carry a risk of transmitting infectious agents, e.g., viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. This also applies to unknown or emerging viruses and other pathogens. No cases of transmission of viral diseases or CJD have been associated with the use of CUTAQUIG. All infections suspected by a physician to have possibly been transmitted by CUTAQUIG should be reported to Pfizer Inc. at 1-800-438-1985. 5.9 Interference with Laboratory Tests After infusion of CUTAQUIG, the transitory rise of the various passively transferred antibodies in the patient’s blood may yield false positive serological test results, with the potential for misleading interpretation. Passive transmission of antibodies to erythrocyte antigens (e.g.. A, B, and D) may cause a positive direct or indirect antiglobulin (Coombs’) test.
Adverse reactions cross-check#
openFDA text is shown for search and cross-checking; DailyMed SPL is canonical.
adverse reactions
6 ADVERSE REACTIONS The most common adverse reactions (AR) observed in ≥ 5% of study subjects were local infusion site adverse reactions (such as redness, swelling, and itching), headache, fever, dermatitis, asthma, diarrhea, and cough. The most common adverse reactions (≥ 5% of study subjects) were local infusion site reactions (such as redness, swelling, itching), headache, fever, dermatitis, asthma, diarrhea, and cough. ( 6 ) To report SUSPECTED ADVERSE REACTIONS, contact Pfizer Inc. at 1-800-438-1985 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice. Clinical safety data are based on one pivotal open-label, single arm, prospective, multicenter major effectiveness study of CUTAQUIG in subjects with primary humoral immunodeficiency (PI), previously treated with Immune Globulin Intravenous (Human) (IGIV) for at least 6 months and its extension study. The pivotal study was conducted in Europe and North America and was followed by an extension safety study (prospective, open-label, single-arm, multicenter phase 3). 21 patients were initially treated in the pivotal study and 6 patients from Canada were newly treated. Total number of patients in both studies combined was 81. In the pivotal study, the 75 subjects in the Safety Analysis Set received 4462 infusions, with a mean of 59 infusions administered per subject. The average dose of CUTAQUIG used per subject was 0.187 g/kg in adult subjects, 0.150 g/kg in young children, 0.164 g/kg in older children and 0.170 g/kg in adolescents. In the extension study, the 27 subjects in the Safety Analysis Set received 2777 infusions. The average dose of CUTAQUIG used per subject was 0.166 g/kg in adult subjects, 0.127 g/kg in young children, 0.210 g/kg in older children and 0.160 g/kg in adolescents. Excluding infections, a total of 74 out of 81 subjects (91%) experienced 1527 adverse reactions (ARs, defined as adverse events occurring during or within 72 hours of infusion or any adverse events otherwise causally related) in both studies. Of the 1527 ARs 1088 were infusion site reactions. The proportion of infusions with adverse reactions was 0.21. Sixty-one subjects (75%) had at least one systemic AR. Local reactions were the most common ARs and were experienced by 59 subjects (73%). The rate of infusion site reaction per infusion was 0.15. Most local ARs were either mild (transient AR causing discomfort but not interfering with routine activities [87.5%]) or moderate (AR sufficiently discomforting to interfere with routine activities [10.3%]) in intensity. Table 3 and Table 4 summarize adverse reactions occurring in ≥ 5% of adult subjects and pediatric subjects in both the pivotal and the extension study. Table 3 Adverse reactions* in ≥ 5% of adult subjects and rate per infusion in adult subjects (pivotal and extension study) ARs Number (%) of subjects (N=43) Number (rate**) of ARs (N=3956 infusions) Local reaction 31 (72.1) 648 (16.4) Systemic ARs Headache 8 (18.6) 10 (0.002) Dermatitis 5 (11.6) 6 (0.001) Fever 5 (11.6) 5 (0.001) Diarrhoea 5 (11.6) 7 (0.002) Muscle spasms 4 (9.3) 5 (0.001) Back pain 4 (9.3) 4 (0.001) Arthralgia 3 (7.0) 3 (0.001) * Excluding infections. ** Rate = total number of adverse reactions divided by total number of infusions. Table 4 Adverse reactions* in ≥ 5% pediatric subjects and rate per infusion in pediatric subjects (pivotal and extension study) ARs Number (%) of subjects (N=38) Number (rate**) of ARs (N=3283 infusions) Local reaction 28 (73.7) 442 (13.5) Systemic ARs Asthma 4 (10.5) 7 (0.002) Cough 4 (10.5) 5 (0.002) Vomiting 4 (10.5) 5 (0.002) Nasal congestion 3 (7.9) 4 (0.001) Fever 3 (7.9) 4 (0.001) Headache 3 (7.9) 3 (0.001) Alanine aminotransferase increased 3 (7.9) 3 (0.001) Leukopenia 3 (7.9) 3 (0.001) Neutropenia 3 (7.9) 3 (0.001) Dermatitis 2 (5.3) 3 (0.001) Oropharyngeal pain 2 (5.3) 3 (0.001) Urticaria 2 (5.3) 2 (0.001) Aspartate aminotransferase increased 2 (5.3) 2 (0.001) Abdominal pain 2 (5.3) 2 (0.001) Ear pain 2 (5.3) 2 (0.001) * Excluding infections. ** Rate = total number of adverse reactions divided by total number of infusions. The most frequent infusion site reactions were redness, swelling, and itching. During the pivotal study period the incidence of local reactions decreased over time from 37% of infusions triggering an infusion site reaction during the first 4 infusions to around 16% of infusions with an infusion site reaction during the last 4 infusions. 6.2 Postmarketing Experience The following adverse reactions have been identified during post-approval use of immune globulin products administered subcutaneously. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Table 5 summarizes adverse reactions that have been reported during post-marketing use of immune globulin products: Table 5 Adverse reactions reported during post-marketing use of immune globulin products MedDRA System Organ Class (SOC) Adverse reactions Blood and lymphatic system disorders Pancytopenia, leukopenia, hemolytic anemia Immune system disorders Anaphylactic reaction, hypersensitivity reaction, allergic reaction, angioneurotic edema, face edema Psychiatric disorders Agitation Nervous system disorders Loss of consciousness, cerebrovascular accident, aseptic meningitis, seizures, migraine, tremor, paresthesia, dizziness Cardiac disorders Cardiac arrest, tachycardia, palpitations Vascular disorders Thromboembolism, thrombosis, circulatory collapse, hypertension, hematoma Respiratory, thoracic and mediastinal disorders Transfusion-related acute lung injury, acute respiratory distress syndrome, respiratory failure, pulmonary embolism, apnea, cyanosis, hypoxia, pulmonary edema, bronchospasm, dyspnea, cough, wheezing Gastrointestinal disorders Hepatic function abnormal, nausea, vomiting, abdominal distension, abdominal pain upper Skin and subcutaneous tissue disorders Stevens-Johnson syndrome, epidermolysis, erythema multiforme, eczema, urticaria, rash (erythematous), alopecia, skin discoloration, skin mass, skin reaction, skin/infusion site ulceration, skin/infusion site necrosis Musculoskeletal and connective tissue disorders Back pain, arthralgia, pain in extremity, myalgia Renal and urinary disorders (Acute) renal failure General disorders and administration site condition Chills, chest pain, chest discomfort, hot flush, flushing, hyperhidrosis, fatigue, influenza-like illness, malaise Investigations Hepatic enzyme increased, coombs test positive, free hemoglobin present, hemoglobin increased, haptoglobin decreased The following adverse reactions have been identified during post-approval use of CUTAQUIG: dizziness, nausea, pruritus and fatigue. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. To report SUSPECTED ADVERSE REACTIONS, contact Octapharma USA Inc. at 1-866-766-4860 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
adverse reactions table
<table><thead><tr><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> ARs</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Number (%) of subjects </content> <content styleCode="bold"> (N=43)</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Number (rate**) of ARs </content> <content styleCode="bold"> (N=3956 infusions)</content></td></tr></thead><tbody><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Local reaction</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 31 (72.1)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 648 (16.4)</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Systemic ARs</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"/><td align="center" valign="top" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 8 (18.6)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 10 (0.002)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Dermatitis</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (11.6)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 6 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Fever</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (11.6)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Diarrhoea</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (11.6)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 7 (0.002)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Muscle spasms</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (9.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Back pain</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (9.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Arthralgia</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.0)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> ARs</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Number (%) of subjects </content> <content styleCode="bold"> (N=38)</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Number (rate**) of ARs </content> <content styleCode="bold"> (N=3283 infusions)</content></td></tr></thead><tbody><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Local reaction</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 28 (73.7)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 442 (13.5)</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Systemic ARs</content></td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"/><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"/></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Asthma</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (10.5)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 7 (0.002)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Cough</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (10.5)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (0.002)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Vomiting</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (10.5)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 5 (0.002)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Nasal congestion</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Fever</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 4 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Headache</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Alanine aminotransferase increased</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Leukopenia</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Neutropenia</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (7.9)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Dermatitis</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Oropharyngeal pain</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 3 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Urticaria</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Aspartate aminotransferase increased</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Abdominal pain</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (0.001)</td></tr><tr><td align="right" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Ear pain</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (5.3)</td><td align="center" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> 2 (0.001)</td></tr></tbody></table>
adverse reactions table
<table><thead><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> MedDRA System Organ Class (SOC) </content></td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"><content styleCode="bold"> Adverse reactions </content></td></tr></thead><tbody><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Blood and lymphatic system disorders</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Pancytopenia, leukopenia, hemolytic anemia</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Immune system disorders</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Anaphylactic reaction, hypersensitivity reaction, allergic reaction, angioneurotic edema, face edema</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Psychiatric disorders</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Agitation</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Nervous system disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Loss of consciousness, cerebrovascular accident, aseptic meningitis, seizures, migraine, tremor, paresthesia, dizziness </td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Cardiac disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Cardiac arrest, tachycardia, palpitations </td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Vascular disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Thromboembolism, thrombosis, circulatory collapse, hypertension, hematoma</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Respiratory, thoracic and mediastinal disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Transfusion-related acute lung injury, acute respiratory distress syndrome, respiratory failure, pulmonary embolism, apnea, cyanosis, hypoxia, pulmonary edema, bronchospasm, dyspnea, cough, wheezing </td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Gastrointestinal disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Hepatic function abnormal, nausea, vomiting, abdominal distension, abdominal pain upper</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Skin and subcutaneous tissue disorders </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Stevens-Johnson syndrome, epidermolysis, erythema multiforme, eczema, urticaria, rash (erythematous), alopecia, skin discoloration, skin mass, skin reaction, skin/infusion site ulceration, skin/infusion site necrosis</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Musculoskeletal and connective tissue disorders</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Back pain, arthralgia, pain in extremity, myalgia</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Renal and urinary disorders</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> (Acute) renal failure</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> General disorders and administration site condition</td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Chills, chest pain, chest discomfort, hot flush, flushing, hyperhidrosis, fatigue, influenza-like illness, malaise</td></tr><tr><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Investigations </td><td align="left" valign="middle" styleCode="Toprule Botrule Lrule Rrule"> Hepatic enzyme increased, coombs test positive, free hemoglobin present, hemoglobin increased, haptoglobin decreased </td></tr></tbody></table>
Reported adverse events (FAERS/openFDA)#
Adverse event summaries are temporarily unavailable. Other product information remains available.